Clinical Report: Selection of Bevacizumab and Platinum-Based Therapy in Patients with Advanced Cervical Cancer Treated with Pembrolizumab
Background
Cervical cancer is a leading cause of cancer-related mortality globally, particularly in advanced stages. The treatment landscape for advanced cervical cancer has evolved with the introduction of immunotherapy, specifically pembrolizumab, in combination with chemotherapy.
Data Highlights
No numerical data available in the provided source material.
Key Findings
Advanced cervical cancer (ACC) poses significant treatment challenges, especially in metastatic cases.
The GOG 240 trial established bevacizumab as standard care, showing improved overall survival (OS) but with increased severe adverse events.
The KEYNOTE-826 trial demonstrated that pembrolizumab combined with platinum-based chemotherapy significantly prolonged progression-free survival (PFS) and OS.
Exploratory analyses indicated that pembrolizumab improved median OS in patients treated with carboplatin but not in those receiving cisplatin.
No randomized trials have specifically evaluated the impact of platinum agent choice or bevacizumab addition in first-line treatment of ACC.
Clinical Implications
The choice of platinum-based chemotherapy and the addition of bevacizumab in treatment regimens for advanced cervical cancer should be carefully considered, as they may influence overall survival and adverse event profiles. Clinicians should remain informed about the latest trial results to optimize treatment strategies.
Conclusion
The findings from this comparative effectiveness analysis underscore the importance of treatment selection in advanced cervical cancer. Further research is needed to clarify the optimal combinations of therapies.
by Alberto Farolfi, Chiara Casadei, Emanuela Scarpi, Eleonora Paoletti, Caterina Gianni, Michela Palleschi, Nicola Gentili, Marita Mariotti, Sara Testoni, Giandomenico Di Menna, Francesca Rusconi, Alice Andalò, Olga Serra, Filippo Merloni, Marianna Sirico, Roberta Maltoni, Lorenzo Cecconetto, Samanta Sarti, Antonino Musolino
A targeted radiopharmaceutical improves CAR T activity in neuroblastoma models, engineered Tregs suppress allergic asthma, and new gene therapy platforms target MMA and the brain
